Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Paramyxovirus
Report summarizes paramyxovirus study findings from Wake Forest University, Medical Department
December 31st, 2008
"The paramyxovirus simian virus 5 (SV5) is a poor activator of human dendritic cell ( DC) maturation pathways in vitro, and infected DC do not upregulate cell surface costimulatory proteins or secretion of immunomodulatory cytokines. We evaluated the hypothesis that activation of SV5-infected DC would be enhanced by engineering SV5 to express a Toll-like-receptor (TLR) ligand," investigators in the United States report. "To test this hypothesis, a novel virus was engineered such that the gene encoding an intracellular form of the TLR5 ligand flagellin was expressed from the genome of wild-type (WT) SV5 ( SV5-flagellin). Cells infected in vitro with the...
Source: Vaccine Weekly (2008-12-31)
|
